Response to Letter Regarding Article, “Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts”

We appreciate the comments and suggestions made by Apostolakis et al. As they point out, there are several important limitations of our analysis, including the high-risk nature of the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial cohort. Factors associated with stroke or systemic embolism in a selected high-risk population may not be generalizable to other patient populations, including patients not currently being treated with oral anticoagulation. It was for precisely these reasons that we validated our model in the independent and unselected ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) cohort.

In our external validation analyses, we found that use of the R2CHADS2 score improved risk stratification in the ATRIA cohort. When compared with the CHADS2 index, use of the R2CHADS2 resulted in 12% (95% confidence interval, 6% to 19.5%) net reclassification improvement in patients on warfarin. Net reclassification improvement was even more robust in those not receiving oral anticoagulation (net reclassification improvement in patients on warfarin. It was for precisely these reasons that we validated our model in the independent and unselected ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) cohort.

Although we certainly agree that additional validation is warranted, the data from ROCKET AF and ATRIA indicate that stroke risk stratification in patients with atrial fibrillation should include renal function.

Disclosures
Dr Piccini reports receiving research grants from Johnson & Johnson and Boston Scientific and serves as a consultant to Medtronic, Forest Laboratories, Sanofi Aventis, and Johnson & Johnson. Dr Singer is supported, in part, by the Eliot B. and Edith C. Shoolman fund of the Massachusetts General Hospital. He receives consulting fees from Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson & Johnson, Pfizer, and Sanofi. Dr Patel receives honoraria from Johnson & Johnson and Bayer and consulting fees from Ortho McNeil Janssen and Bayer HealthCare and serves on an advisory board for Genzyme. Dr Mahaffey receives grant support from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Momenta Pharmaceuticals, Novartis, Portola, Pozen, Regado Biotechnologies, Sanofi-Aventis, Schering-Plow (now Merck), and The Medicines Company. Dr Mahaffey reports receiving consulting fees from AstraZeneca and Johnson & Johnson, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Momenta Pharmaceuticals, Novartis, Portola, Pozen, Regado Biotechnologies, Sanofi-Aventis, Schering-Plow (now Merck), and The Medicines Company. Dr Mahaffey reports receiving consulting fees from AstraZeneca and Johnson & Johnson, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Momenta Pharmaceuticals, Novartis, Portola, Pozen, Regado Biotechnologies, Sanofi-Aventis, Schering-Plow (now Merck), and The Medicines Company.

Dr Piccini reports receiving research grants from Johnson & Johnson and Bayer and serves on an advisory board for Boehringer Ingelheim. Dr Becker receives research support from Bayer and Johnson & Johnson. Dr Nessel is an employee of Johnson & Johnson. Dr Fox receives research grants and honoraria from Bayer, Eli Lilly, Boehringer Ingelheim, Sanofi-Aventis, and GlaxoSmithKline. Dr Califf receives consulting fees and research funding from Johnson & Johnson. A full list of the disclosures for Drs Piccini, Patel, Mahaffey, and Califf are listed at www.dcri.org. S. Stevens and Drs Chang, Lokhnygina, and Go report no conflicts.

Jonathan P. Piccini, MD
Susanna R. Stevens, MS
Duke Clinical Research Institute
Duke University Medical Center
Durham, NC

YuChiao Chang, PhD
Daniel E. Singer, MD
Massachusetts General Hospital and Harvard Medical School
Boston, MA

Yuliya Lokhnygina, PhD
Duke Clinical Research Institute
Duke University Medical Center
Durham, NC

Alan S. Go, MD
Kaiser Permanente Division of Research
Oakland, CA

Manesh R. Patel, MD
Kenneth W. Mahaffey, MD
Duke Clinical Research Institute
Duke University Medical Center
Durham, NC

Jonathan L. Halperin, MD
Mount Sinai Medical Center
New York, NY

Günter Breithardt, MD
Hospital of the University of Münster
Münster, Germany

Graeme J. Hankey, MD
Royal Perth Hospital
Perth, WA, Australia

Werner Hacke, MD, PhD
Ruprecht Karls University
Heidelberg, Germany

Richard C. Becker, MD
Duke Clinical Research Institute
Duke University Medical Center
Durham, NC

Christopher C. Nessel, MD
Johnson & Johnson Pharmaceutical Research and Development
Raritan, NJ

Keith A. A. Fox, MB, ChB
University of Edinburgh and Royal Infirmary of Edinburgh
Edinburgh, UK

Robert M. Califf, MD
Duke Translational Medicine Institute
Duke University Medical Center
Durham, NC

DOI: 10.1161/CIRCULATIONAHA.113.004013

Correspondence

© 2013 American Heart Association, Inc.
Circulation is available at http://circ.ahajournals.org
References


Response to Letter Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the \( \text{R}_2 \) CHADS\(_2\) Index in the ROC\( \)ET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts"


_Circulation_. 2013;128:e172-e173
doi: 10.1161/CIRCULATIONAHA.113.004013
_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/128/11/e172

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org/subscriptions/